News Story: Full Text
Sponsored By
AbbVie
Please Click On The Above Banner For More Details
Braintumor Website


   Share  

Prolonged and severe myelosuppression in two patients after low-dose temozolomide treatment- case study and review of literature.


Posted on: 03/18/2008

J Neurooncol. 2007 Nov;85(2):229-30. Epub 2007 May 26.

Click here to read 
Prolonged and severe myelosuppression in two patients after low-dose temozolomide treatment- case study and review of literature.

Singhal N, Selva-Nayagam S, Brown MP.

Department of Medical Oncology, Royal Adelaide Hospital, Adelaide, SA, 5000, Australia. nsinghal@mail.rah.sa.gov.au

Temozolomide is an alkylating agent used frequently in the management of gliomas. Although temozolomide is generally safe, rarely it can cause life threatening complications. Here we report the cases of two patients who developed prolonged and severe pancytopenia after low dose continuous temozolomide concurrently with cranial radiotherapy. The pancytopenia lasted two to six months. Both the patients were young, treatment naive, and had temozolomide treatment for only approximately four weeks.

Publication Types:
  • Case Reports
  • Review

PMID: 17530175 [PubMed - indexed for MEDLINE]

Click HERE to return to brain tumor news headlines


Home | Brain Tumor Guide | FAQs | Find A Treatment
Noteworthy Treatments | News | Virtual Trial | Videos | Novocure Optune® | Newsletter
Donations | Brain Tumor Centers | Survivor Stories | Temodar®
Fundraising For Research | Unsubscribe | Contact Us

Copyright (c) 1993 - 2017 by:
The Musella Foundation For Brain Tumor Research & Information, Inc
1100 Peninsula Blvd
Hewlett, NY 11557
888-295-4740


Website Design By
World Wide Websites